StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
AHC-R.BK$12.50-5.30%
Fair $12.50+0.0%

AHC-R.BK

Aikchol Hospital Public Company Limited

Healthcare / Medical Care FacilitiesThailand

$12.50

-0.70 (-5.30%)

Fairly Valued+0.0%Fair Value $12.50Fund rank 36/100 · Data gapFallback financials|
SA 48/C
F-Score: 5/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 24% · confianza 25%

FCF escenarios

weak_data · normalized FCF $154.0M · quality 79.7/100

Data gap 36/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 74/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

48/100

C

Piotroski

5/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · AHC-R.BKLocal privado en este navegador · Aikchol Hospital Public Company Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$1.9B

P/E

14.7x

↓

EV/EBITDA

5.9x

↓

ROE

7.1%

↑

Gross Margin

20.9%

↓

Debt/Equity

0.00

↓
52-Week Range$13
$12$15

TradingView lightweight chart

AHC-R.BK price, volumen y niveles de valoración

Último $12.50Periodo +1495.7%
Fair value: $12.50

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-2.7%

FCF CAGR

-8.1%

FCF margin

8.7%

FCF / Net income

1.02x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $1.80B · net income $153.7M · FCF $156.7M

2022-FY → 2025-FY

Gross margin

20.9%-5.6% pts

Operating margin

8.3%-7.5% pts

Net margin

8.5%-5.3% pts

FCF margin

8.7%-1.6% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$1.80B$1.80B$1.76B$1.79B$1.96B
Net Income$153.7M$153.7M$127.0M$188.8M$271.1M
EBITDA$280.4M$280.4M$242.0M$309.4M$409.3M
EPS——0.851.261.81
Gross Margin20.9%20.9%18.5%23.4%26.5%
Operating Margin8.3%8.3%6.3%11.1%15.8%
Net Margin8.5%8.5%7.2%10.5%13.8%
Balance Sheet
Debt/Equity0.000.000.000.000.00
Current Ratio6.546.54———
Cash Flow
Free Cash Flow$156.7M$156.7M$104.8M$154.0M$201.8M
Returns
ROE7.1%7.1%6.1%9.1%13.1%
Valuation
P/E14.7114.7118.4513.659.72
EV/EBITDA5.905.908.707.676.01
P/B0.870.871.121.241.28
Growth & Yield
Revenue Growth2.6%2.6%-2.0%-8.5%—
EPS Growth——-32.5%-30.4%—
Dividend Yield3.9%3.9%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -6.8%

Total return

-6.8%

Start / end P/E

n/dx → n/dx

EPS bridge

0.85 → n/d

Residual

-10.7%

EPS growthn/d
Multiple reratingn/d
Dividend+3.9%
Residual / FX / buybacks / cross-term-10.7%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.